This randomized controlled clinical trial evaluates neurocognitive, biopsychological, and brain connectome outcomes in children and adolescents with acute lymphoblastic leukemia who have previously received Chimeric Antigen Receptor T-cell therapy (CAR T-cell therapy), chemotherapy, and/or hematopoietic stem cell transplantation (HSCT). Participants will receive a multimodal, telematic psychological intervention combining digital cognitive training and an adapted mindfulness-based emotional regulation program. Outcomes will be compared with a waitlist control group and intervention sequences will be counterbalanced: (1) cognitive training followed by mindfulness; and (2) mindfulness followed by cognitive training. Neurocognitive performance, emotional-behavioral functioning, executive functioning and EEG-based functional connectivity will be assessed at baseline, post-intervention and at 6 months follow-up.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Symbol Digit Modalities Test (SDMT).
Timeframe: Baseline
Continuous Performance Test, third edition (CPT-3)
Timeframe: Baseline
Clinical Assessment of Memory (ECM)
Timeframe: Baseline
Verbal Fluency Test (VFT)
Timeframe: Baseline
Stroop. Test of Colors and Words. Revised edition.
Timeframe: Baseline
Symbol Digit Modalities Test (SDMT)
Timeframe: 6 months
Continuous Performance Test, third edition (CPT-3)
Timeframe: 6 months
Clinical Assessment of Memory (ECM)
Timeframe: 6 months
Stroop. Test of Colors and Words. Revised edition
Timeframe: 6 months
Verbal Fluency Test (VFT)
Timeframe: 6 months